INTRODUCTION {#sec1-1}
============

According to the cancer incidence report in Saudi Arabia for the year 2013, there were 280 new cases of urinary bladder cancer, accounting for 4.3% and 0.8% of all newly diagnosed cases of cancer in men and women, respectively. Urinary bladder cancer is ranked the 8^th^ most common cancer in males and the 20^th^ most common in females. Of the 280 cases, 227 affected males (81%) and 53 affected females (19%). The overall age-standardized incidence rate was 3.8/100,000, in males and 1/100,000 in females. The median age at diagnosis was 63 years among males and 64 years among females.\[[@ref1]\]

STAGING {#sec1-2}
=======

The American Joint Committee on Cancer tumor, nodes, metastases staging definitions for bladder cancer should be used\[[@ref2]\] \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Tumor, node, and metastasis staging for urothelial bladder carcinoma
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###### 

Urothelial bladder carcinoma anatomical stages and prognostic groups
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TUMOR GRADING {#sec1-3}
=============

The 2016 World Health Organization Classification of Tumors of the Urinary System\[[@ref3]\] will be used as follows:\[[@ref4]\]

Noninvasive urothelial lesionsUrothelial carcinoma *in situ*Papillary urothelial carcinoma, low gradePapillary urothelial carcinoma, high gradePapillary urothelial neoplasm of low malignant potential.Urothelial papillomaInverted urothelial papillomaUrothelial proliferation of uncertain malignant potential (hyperplasia)Urothelial dysplasiaInvasive urothelial tumor.

PATHOLOGY REPORTING {#sec1-4}
===================

Surgical pathology reporting must include the following:

The histological tumor typeThe presence or absence of lamina propria and muscularis propriaThe depth of invasion (i.e., pathological T stage) referred to in Section 1The presence or absence of carcinoma *in situ* (CIS)The grade of tumor as referred to in Section 2Any urothelial carcinoma variant.\[[@ref5]\]

EVALUATION OF THE BLADDER TUMOR {#sec1-5}
===============================

The initial evaluation should include history and physical examination, complete blood count, renal function, urine cytology, and bladder ultrasonography. Initial diagnostic cystoscopy should be done with transurethral bladder tumor resection (TURBT) to achieve complete resection if possible.\[[@ref6]\] Imaging of the upper tract should be done by ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) urogram. If the cystoscopy findings confirm the invasive disease, do CT or MRI of abdomen and pelvis, as well as chest imaging.\[[@ref7][@ref8]\]

MANAGEMENT OF NONMUSCLE INVASIVE UROTHELIAL BLADDER CARCINOMA {#sec1-6}
=============================================================

If the findings of the diagnostic cystoscopy are suggestive of a noninvasive bladder tumorConduct TURBT to achieve complete resection, if possibleRepeat TURBT within 2--4 weeks, indicated if the resection was incomplete, the disease is high-grade Ta or T1, or if no muscle examination was performedAdminister a single postoperative instillation of intravesical chemotherapy (e.g., mitomycin C or epirubicin/doxorubicin) within 24 h of TURBT, unless perforation is suspected\[[@ref9][@ref10][@ref11]\]Provide further treatment according to risk stratification.Risk stratification for nonmuscle invasive urothelial bladder carcinomaRisk depends on the following factors: T stage, the presence of CIS, grade, recurrence rate, number of tumors, and tumor size\[[@ref12]\] \[[Table 3](#T3){ref-type="table"}\]\[[@ref13]\]Low-risk, nonmuscle, invasive bladder cancer (NMIBC) (solitary small volume, low-grade Ta)Intermediate risk NMIBC (multifocal and/or large volume low-grade Ta, recurrence at 3 months)High-risk NMIBC (high-grade Ta, all T1, CIS).Management of low-risk NMIBC-- Surveillance cystoscopy (3--6 months) intervals \[[Table 4](#T4){ref-type="table"}\]Management of intermediate risk NMIBC:Intravesical bacillus Calmette--Guerin (BCG) or mitomycin induction (weekly for 6 weeks)\[[@ref14]\]Surveillance cystoscopy and cytologyUpper tract imaging every 2 years or as indicated.Management of high-risk nonmuscle, invasive bladder cancer, including carcinoma *in situ*Intravesical BCG or mitomycin induction (weekly for 6 weeks) and maintenance therapy (3 weekly injections) at 3, 6, 12, 18, 24, 30, and 36 months from induction\[[@ref15][@ref16]\]Close surveillance cystoscopy, cytology, and upper tract imagingConsider early cystectomy in selected patients.Recurrence of nonmuscle invasive diseaseTURBTAdjuvant intravesical therapy if not given before or as a second induction\[[@ref17]\]If two inductions of adjuvant intravesical therapy were given before, then consider changing the intravesical therapyConsider early cystectomy in recurrent CIS, T1, and high-grade disease with prior treatment with no \>2 inductions of intravesical therapy.\[[@ref18][@ref19]\]Positive urine cytology without gross evidence of diseaseMultiple biopsies of the bladder and prostatic urethra\[[@ref20][@ref21][@ref22]\]Selective cytology of the upper tractUpper tract imaging (CT, MRI, or retrograde pyelogram)Ureteroscopy if suspicion of upper tract tumor.

###### 

Risk stratification for nonmuscle invasive urothelial bladder carcinoma
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###### 

Suggested follow-up schedule for nonmuscle invasive disease

![](UA-10-133-g004)

MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA {#sec1-7}
==========================================================

Staging should include complete blood count; renal function; serum electrolytes; liver function test, including alkaline phosphatase; imaging of the chest, abdomen, and pelvis (CT or MRI); and a bone scan if elevated alkaline phosphatase or symptoms of bone pain are present.\[[@ref23]\]

Clinical T2--T4a disease with negative lymph nodesNeoadjuvant cisplatin-based combination chemotherapy:\[[@ref24][@ref25][@ref26]\]Considered in clinical T2Strongly recommended in clinical T3.Radical cystectomy with extended lymphadenectomy (open, laparoscopic, or robotic) is considered the standard treatment\[[@ref27]\]Bilateral pelvic lymphadenectomy should be performed and include, at a minimum, the common, internal and external iliac, and obturator nodesBladder preservation with trimodality combination of complete resection of the bladder tumor TURBT, followed by concurrent chemoradiation with early radical cystectomy in failure, are alternatives to upfront radical cystectomy\[[@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\] in selected patients with solitary disease, no CIS, no hydronephrosis, normal renal function, and adequate bladder capacity\[[@ref33]\]In patients undergoing bladder preservation, early evaluation by cystoscopy with or without biopsy is recommended after 40--45 Gy for the whole bladder and regional nodes. If there is residual/recurrent tumor, then consider cystectomy. If there is complete response, then complete radiotherapy to 60--65 Gy total dose in conventional fractionation; altered fractionation regimens, such as 50--52.5 Gy in 20 fractions, may also be considered\[[@ref34]\]For patients who are not candidates for radical treatment, consider TURBT and/or palliative radiotherapyIf no neoadjuvant chemotherapy is given, consider adjuvant cisplatin-based chemotherapy following pathological criteria (pT3--4, positive nodes).\[[@ref35]\]Clinical T4b or positive locoregional lymph node diseaseCisplatin-based combination chemotherapy or chemoradiationReevaluate the response during the treatment with imaging and/or TURBTIf chemoradiation was used:Observation for patients who achieved complete response.If partial response, consider cystectomy.If cisplatin-based combination chemotherapy was used:In responding patients, consider cystectomy or chemoradiationIn nonresponding patients, consider chemoradiation.Metastatic diseaseChemotherapy is the mainstay of treatmentPatients with normal renal function and fit for chemotherapy (performance status \[PS\] 0--2) are treated with combination cisplatin and gemcitabine for a maximum of six cycles\[[@ref36]\]Patients with decreased renal function and/or unfit (PS 3) are treated with combination of carboplatin and gemcitabine\[[@ref37]\] or single-agent gemcitabine, carboplatin, or atezolizumab\[[@ref38]\]There is no standard, second-line therapy; patients who relapse or progress on the first-line may be given atezolizumab,\[[@ref38]\] vinflunine, or taxanes as second-line chemotherapyPatients who present with local recurrence may benefit from palliative radiation therapy.
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